Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 671800 ED versus fluticasone and placebo in mild steroid-naïve asthma
2010-023326-20Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BI-671800 in asthma (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: FEV1 % predicted trough change at 6 weeks. Started Nov 2010; status: terminated.
02
Drugs
BI-671800
03
Conditions
asthma
Beyond the preview
Go deeper on 2010-023326-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023326-20.